Drug Trial Radar · NCT01581593
Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)
Last checked: Nov 20, 2026Latest source record: Feb 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Nov 12, 2012
Primary completion
Aug 27, 2014
Study completion Aug 27, 2014
Sponsor
- Lead sponsor
- Kedrion S.p.A.Industry
- Sponsor type
- Industry
- First posted
- Apr 20, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether Kedrion IVIG 10% (an immunoglobulin solution) is effective in treating Primary Immunodeficiency (PID).
Conditions
- Primary Immunodeficiency
- Agammaglobulinemia
- Hypogammaglobulinemia
- Antibody Deficiency
Interventions
Kedrion IVIG 10%Biological
Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Treatment duration - 12 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Acute, Serious Bacterial Infections in the Total ITT Population.Time frame: 13 months
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas
Allergy Associates of the Palm Beaches
North Palm Beach, Florida
Family Allergy & Asthma Center, PC
Atlanta, Georgia
Rush University
Chicago, Illinois
University of Iowa Hospital and Clinics
Iowa City, Iowa
Midwest Immunology Clinic
Plymouth, Minnesota
AAIR Research Center
Rochester, New York
Optimed Research, LTD
Columbus, Ohio
Dallas Allergy Immunology Research
Dallas, Texas
AARA Research Center
Dallas, Texas
Virginia Commonwealth University Health Systems
Richmond, Virginia
Marycliff Allergy Specialists
Spokane, Washington
Gordon Sussman Clinical Research Inc.
Toronto, Ontario, Canada
Pediatric & Adult Allergy & Clinical Immunology
Toronto, Ontario, Canada
The Hospital for Sick Children
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.